Results 31 to 40 of about 44,090 (228)

Trigeminal neuralgia

Diagnostic and Interventional Imaging, 2013
Two different clinical entities, essential or secondary neuralgia, are associated with different pathologies. The pathways of CN V comprise the cervical spine, the brainstem, the root of the nerve and the three peripheral branches: V1, V2 and V3.
Leclercq, D., Thiebaut, J.-B., Héran, F.   +2 more
openaire   +2 more sources

Trigeminal Nerve Root Demyelination Not Seen in Six Horses Diagnosed with Trigeminal-Mediated Headshaking

Frontiers in Veterinary Science, 2017
Trigeminal-mediated headshaking is an idiopathic neuropathic facial pain syndrome in horses. There are clinical similarities to trigeminal neuralgia, a neuropathic facial pain syndrome in man, which is usually caused by demyelination of trigeminal ...
Veronica L. Roberts, Debra Fews, Jennifer M. McNamara, Seth Love   +3 more
doaj   +1 more source

Neuralgia del trigémino clásica familiar

Neurología, 2019
Resumen: Introducción: La neuralgia del trigémino clásica es un cuadro habitualmente esporádico, sin asociación familiar. Pero se estima que hasta un 2% de las neuralgias del trigémino podrían ser de tipo familiar.
B. Fernández Rodríguez, C. Simonet, D.M. Cerdán, N. Morollón, P. Guerrero, C. Tabernero, J. Duarte   +6 more
doaj   +1 more source

Pharmacotherapy of trigeminal neuralgia

, 2022
Trigeminal neuralgia is the most common type of facial pain syndrome that involves areas of skin innervated by one or multiple branches of the trigeminal nerve.The primary focus of this thesis is to discuss available pharmacological treatments for ...
Zahedi, Amirbahador
core  

Role of Platelet-Rich Plasma as an Adjunct Therapy in Trigeminal Neuralgia- A Novel Follow-Up Study

Journal of Indian Academy of Oral Medicine and Radiology
Background: Despite promising theoretical benefits, there is a paucity of clinical evidence supporting the use of PRP in managing Trigeminal Neuralgia. This study aims to investigate the potential benefits and efficacy of PRP in Trigeminal Neuralgia, a ...
Puneeta Vohra, Pratibha Rajput, Astha Chaudhry, Sumridhi Aggarwal   +3 more
doaj   +1 more source

Clinical characteristics of pain in patients with trigeminal neuralgia: data from a neurosurgical clinic

Українська Інтервенційна Нейрорадіологія та Хірургія, 2023
Among the pain syndromes caused by damage to cranial nerves, trigeminal nerve pathology occupies the main place. Trigeminal neuralgia is an exhausting condition characterized by acute shooting recurrent pain in the face.
V.V. Smolanka
doaj  

c-Abl-p38 signaling pathway mediates dopamine neuron loss in trigeminal neuralgia

Molecular Pain, 2020
Trigeminal neuralgia is a common neuropathic pain in the head and face. The pathogenesis of trigeminal neuralgia is complex, and so far, the pathogenesis of trigeminal neuralgia involving peripheral and central nervous inflammation theory has not been ...
Jia Fu, Guo Mu, Ling Qiu, Jiaomei Zhao, Cehua Ou   +4 more
doaj   +1 more source

Radiofrequency thermocoagulation of Gasserian ganglion in trigeminal neuralgia

Journal of Education, Health and Sport
Introduction: Trigeminal neuralgia (TN) is a form of neuropathic pain that targets the fifth cranial nerve, leading to intense facial pain that can significantly impact one’s quality of life.
Natalia Maria Rulewska, Filip Grabowski, Dagmara Neska, Jakub Siemko, Dominika Prystacka-Szar, Justyna Stadler-Szajda, Adrianna Czyżnikiewicz, Wenancjusz Stołowski, Magdalena Bujak, Magdalena Waśniowska, Jakub Chodkowski   +10 more
doaj   +1 more source

Narrow ovale foramina may be involved in the development of primary trigeminal neuralgia

Frontiers in Neurology, 2022
BackgroundThe etiology of primary trigeminal neuralgia remains unclear and is worthy of further study; In this study, the morphometric characteristics of ovale foramina between various groups were compared and analyzed to explore the novel cause of ...
Shuo Li, Chenlong Liao, Meiqiong Qian, Xiaosheng Yang, Wenchuan Zhang   +4 more
doaj   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon, Chutima Seree‐aphinan, Antida Sangiemchoey, Khwanchanok Kaewpiboon, Taweesak Maneerot, Oradawan Plong‐on, Pornsiri Sangmanee, Punthipa Nichanon, Jariya Khayman, Jiraphan Manee, Areerat Hnoonual, Kanoot Jaruthamsophon   +11 more
wiley   +1 more source